Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023

Author's Avatar
Apr 11, 2023

Company to share preliminary safety and efficacy data from ongoing Phase 1/2 trial of OCU400 for the treatment of retinitis pigmentosa and Leber congenital amaurosis